- IN BRIEF
A type 1 regulatory T cell-based therapy
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 20, 898 (2021)
doi: https://doi.org/10.1038/d41573-021-00183-8
References
Chen, P. P. et al. Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Sci. Transl Med. 13, eabf5264 (2021)